ClinicalTrials.gg
RecruitingNCT07388628ARTistryUpdated Jul 15, 2026

ARTICE® Real Data Collection & Observational Trial, Phase 4 Study

An observational study in Sepsis, Septic Shock and Immunoparalysis in Septic Shock, sponsored by Artcline GmbH. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Artcline GmbH · Observational

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Shock, Septic with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Shock, Septic · Germany.

Planned enrollment
15th of 26
200 · median 275
Started
2025
with 1 other
Observational
27 of 56
5 open now
Registered
55th of 56
by date

Among the 56 studies in Shock, Septic with a site in Germany, this one is the 15th largest by planned enrollment of the 26 observational ones that give a count, is one of 2 that started in 2025, is one of 27 observational ones, and was the 55th registered.

Shock, Septic

1,078 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

7 of the 56 studies in Shock, Septic with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Shock, Septic with a site in Germany, or all of them as a file.
02

Study summary

The objectives of this registry study are to:

  1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects.
  2. Further evaluate ARTICE® treatment efficacy.
  3. Identify potential sub-groups, assess their risk-benefit- and safety profile.
  4. Changes in SOFA score D0 to SOFA Score D7.
03

Conditions studied

  • Sepsis
  • Septic Shock
  • Immunoparalysis in Septic Shock

Browse trials for

Keywords

  • Sepsis
  • septic shock
  • Immunoparalysis in Septic Shock
04

In context

Shock, Septic Reclassified

1,078 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

This study's planned enrollment of 200 is above the median of 110 across 407 observational studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Artcline GmbH is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥ 18 years who are planned to receive ARTICE® treatment during their ICU stay

Exclusion criteria

Exclusion Criteria:

-

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
7 Days
Patient registry
Yes
07

What researchers measure

Primary outcomes

  1. Change in SOFA score D0 to SOFA Score D7 (or after last ARTICE® treatment, if later as D7).

    SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  2. Changes in general SOFA score and SOFA sub scores.

    SOFA Score is the Sequential Organ Failure Score providing information about mortality risk, 6 organs or organ systems are assesed using specific parameters, both the sum of the points and the point development of the individual organs can be considered, normal function of organ/organ system has 0 points, severely impacted function do have 4 point, in total you can have 0 points (every organ/organ system is normale) as a minimum and 24 points as maximum (severely impacted organ/organ system)

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  3. Changes in standard lab and inflammatory biomarkers.

    standard lab and inflammatory biomarkers for exampample are: ferritine, total bilirubin, kreatinine, CRP, lactate, gammaglobuline, amount of the different blodd cell types, like neutrophils, lymphocytes

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  4. Hospital survival rates.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  5. Apache II Score.

    APACHE II is a clinical rating system for evaluating the severity of an illness and the risk of death in intensive care medicine; score includes information on the patient's current condition, age and concomitant diseases, values are collected over 24 hours, highest value is included in calcutaion; the score can be at minimum 0 points (lightly risk of death) and at maximum 71 (very high risk of death)

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  6. Length of ICU stay (days).

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  7. Mechanical ventilation days.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  8. Renal replacement therapy days.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  9. Vasopressor therapy days.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  10. Frequency of secondary infections.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  11. Type of secondary infections: it will be divided into viral, bacterial or fungi infection.

    It is recorded whether the infection is viral, bacterial, or caused by fungi. And in case of bacterial infection it will be recorded weather, it is gram-positive or gram-negative bacterial infection.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  12. Changes in the physiological parameter heartrate.

    as physiological parameter will be measured heartrate in bpm

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  13. Changes in physiological parameter blood pressure.

    as physiological parameter will be measured systolic and diastolic blood pressure in mmHg.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  14. Changes in physiological parameter body temperature.

    as physiological parameter will be measured body temperature in °C

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  15. Changes in physiological parameter mean arterial pressure.

    as physiological parameter will be measured mean arterial pressure in mmHG

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

  16. Complications related to the ARTICE® therapy application.

    Time frame: From enrollment up to 7 days after last ARTICE® treatment.

08

Study locations

2 of 2 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 202 observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 5, 2026
StartActual
Sep 25, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07388628
Lead sponsor
Artcline GmbH
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Sep 25, 2025
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Jens Altrichter, Dr. med.
Contact
jens.altrichter@artcline.de
+49 381 440 703 0
Judith Hey, M. Sc.
Contact
judith.hey@artcline.de
+49 1772216033
Martin Sauer, Prof. Dr. med.
principal investigator · Klinikum Magdeburg, Klinik für Intensiv- & Rettungsmedizin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion